One such drug is tucatinib, a next-generation small molecule TKI that is currently under assessment for improving outcomes specifically among patients with HER2+ BC with BM (ClinicalTrials.gov: NCT02614794 and NCT03975647) [46]. This evidence concerns the gene ERBB2 and breast cancer.